'Barely-Disguised' Dividend Hike Boosts AstraZeneca Shares Ahead of Pay Vote |
Equity Research & Insights |
Ollie Smith |
11/04/24 |
Stock of the Week: Moderna |
Equity Research & Insights |
Andrew Willis |
05/09/22 |
What a Covid-19 Vaccine Means for Investors |
Equity Research & Insights |
Karen Andersen, CFA |
21/07/20 |
Healthcare Stocks for a Healthy Retirement |
Investor Views |
Emma Simon |
19/02/20 |
Reckitt Shares Rise After Suboxone Settlement |
Equity Research & Insights |
James Gard |
11/07/19 |
Top Asian Healthcare Stocks |
Perspectives |
External Writer |
09/04/19 |
How to Tap Into the Genetics Revolution |
Perspectives |
EdenTree |
29/03/19 |
Can Healthcare Stocks Continue their 2018 Rally? |
Equity Research & Insights |
David Brenchley |
30/01/19 |
GSK Pfizer Joint Venture No Impact on Company Value |
Equity Research & Insights |
Damien Conover, CFA |
20/12/18 |
Healthcare Stocks Aren't Cheap But Offer Attractive Returns |
Equity Research & Insights |
Philip Straehl |
22/11/18 |
Henderson Backs Two Tech Alternative Trusts |
Investment Trust Research & Insights |
David Brenchley |
25/09/18 |
Healthcare: Profit from an Ageing Population |
Market Update |
Emma Wall |
17/09/18 |
ETF Investors Look to Healthcare Stocks |
ETF Research & Insights |
David Brenchley |
13/09/18 |
GlaxoSmithKline Shares Still Undervalued |
Equity Research & Insights |
Damien Conover |
31/07/18 |
Shire Stock Undervalued Despite Takeover Bid |
Equity Research & Insights |
Karen Andersen, CFA |
20/04/18 |
Can FTSE 100 Drug Giants Weather US Reforms? |
Equity Research & Insights |
Damien Conover |
29/03/18 |
Takeda Takeover Bid for Shire: Analyst View |
Equity Research & Insights |
Karen Andersen, CFA |
29/03/18 |
Novartis Deal Will Strengthen Glaxo's Dividend say Analysts |
Equity Research & Insights |
Damien Conover, CFA |
28/03/18 |
Glaxo Dividend Cut Unlikely say Analysts |
Equity Research & Insights |
Damien Conover |
26/10/17 |
Revealed: The Funds Hit by AstraZeneca Slump |
Fund Research & Insights |
Karen Kwok |
27/07/17 |
AstraZeneca Falls 16% as Drug Trial Falters |
Equity Research & Insights |
Emma Wall |
27/07/17 |
Pfizer Offers Dividend Opportunity |
Equity Research & Insights |
Damien Conover, CFA |
07/06/17 |
Biotech Trusts Trade at Discount |
Investment Trust Research & Insights |
Karen Kwok |
26/05/17 |
Are Healthcare Stocks Too Expensive? |
Equity Research & Insights |
Dan Kemp |
02/05/17 |
Will Trump’s Policies Provide a Boost or Brake on Healthcare Funds? |
Fund Research & Insights |
Sam Shaw |
07/02/17 |
UK Pharma Stocks Fall as Trump Repeals Obamacare |
Equity Research & Insights |
Karen Kwok |
02/02/17 |
Pharma Stocks Remain Undervalued Despite Clinton Loss |
Equity Research & Insights |
Karen Kwok |
29/11/16 |
What Does President Trump Mean for Healthcare Stocks? |
Equity Research & Insights |
Damien Conover, CFA |
10/11/16 |
Healthcare and Mining Stocks Gain On Trump Win |
Equity Research & Insights |
Karen Kwok |
09/11/16 |
AstraZeneca Shares Upgraded Thanks to Weak Sterling |
Equity Research & Insights |
Damien Conover, CFA |
24/10/16 |
Why Healthcare Stocks Will be the Real Winner of the US Election |
Equity Research & Insights |
Karen Kwok |
26/09/16 |
How the US Election is Creating Investment Opportunities |
Equity Research & Insights |
Daniel Vaughan, CFA |
26/04/16 |
JPMorgan: We're Shorting Emerging Markets |
Equity Research & Insights |
Emma Wall |
22/04/16 |
US Election is the Biggest Challenge to Healthcare Stocks |
Equity Research & Insights |
Karen Kwok |
14/04/16 |
Analysts Downgrade Shire |
Equity Research & Insights |
Stefan Quenneville, CFA |
15/02/16 |
AstraZeneca Credit Rating Downgraded by Analysts |
Bond Investing |
Morningstar Credit Committee |
03/12/15 |
AstraZeneca Fairly Valued after Solid Q3 |
Equity Research & Insights |
Damien Conover, CFA |
10/11/15 |
Smith & Nephew Ripe for Takeover Bid say Analysts |
Equity Research & Insights |
Debbie S. Wang |
20/10/15 |
Pharmaceutical Stocks Get Sales Boost from Clinical Report |
Equity Research & Insights |
Damien Conover, CFA |
15/05/15 |
Investment Focus: AstraZeneca |
Equity Research & Insights |
Damien Conover, CFA |
12/05/15 |
AstraZeneca is Overvalued |
Equity Research & Insights |
Damien Conover, CFA |
27/04/15 |
4 Pharma Stocks Best Placed in Cancer Market |
Equity Research & Insights |
Stefan Quenneville, CFA |
30/03/15 |
Outperforming Manager Picks 3 Stocks to Get Rich Slowly |
Fund Research & Insights |
Emma Wall |
17/02/15 |
Morningstar's View on Major Company Earnings and M&A |
Equity Research & Insights |
Holly Cook |
06/02/15 |
Is Glaxo's Dividend at Risk? |
Equity Research & Insights |
Damien Conover, CFA |
05/02/15 |
What Next for Pharmaceuticals? |
Equity Research & Insights |
Matthew Coffina, CFA |
30/12/14 |
Woodford Blog: Will Pfizer Make Another Bid for Astra? |
Perspectives |
Woodford Funds |
18/11/14 |
What's in the Pipeline for AstraZeneca |
Equity Research & Insights |
Damien Conover, CFA |
07/11/14 |
British Pharmaceutical Companies Lag Global Peers |
Equity Research & Insights |
Damien Conover, CFA |
04/11/14 |
Astra Shares Worth £35 |
Equity Research & Insights |
Damien Conover, CFA |
04/06/14 |